Discrepancy in current central serous chorioretinopathy classification

Singh, Sumit Randhir; Matet, Alexandre; Dijk, Elon H. C. van; Daruich, Alejandra; Fauser, Sascha; Yzer, Suzanne; Peiretti, Enrico; Sivaprasad, Sobha; Lotery, Andrew; Boon, Camiel J F; Béhar-Cohen, Francine; Freund, K. Bailey; Chhablani, Jay

doi:10.1136/bjophthalmol-2018-312435

Cited by 45 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even so, temporal and phenotype criteria (structural changes) are currently the only universally accepted criteria for classifying and distinguishing CSC. However, overlapping discrepancies and terminologies are excessive even among experts, and this creates a strong limitation in the development of management strategies [32,33]. Singh et al [33] conducted a multicenter survey with multimodal images of 100 acute and chronic CSC cases.…”

Section: Classification Modelsmentioning

confidence: 99%

“…However, overlapping discrepancies and terminologies are excessive even among experts, and this creates a strong limitation in the development of management strategies [32,33]. Singh et al [33] conducted a multicenter survey with multimodal images of 100 acute and chronic CSC cases. Agreement between classification and descriptor terms used among the graders was poor.…”

Section: Classification Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Central Serous Chorioretinopathy Classification

Vilela

Mengue²

2020

Pharmaceuticals

View full text Add to dashboard Cite

Central serous chorioretinopathy is characterized by an idiopathic neurosensory detachment of the retina. This narrative review aims to discuss the classification system used for central serous chorioretinopathy. Based on our current knowledge, there is no universally adopted classification system. This is the result of the unknown aspects related to pathogenesis and clinical spectrum and evolution. The best option could be to aggregate multimodal pieces of information alongside temporal and phenotypic characteristics.

show abstract

Section: Classification Modelsmentioning

confidence: 99%

Section: Classification Modelsmentioning

confidence: 99%

Central Serous Chorioretinopathy Classification

Vilela

Mengue²

2020

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Central serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium (RPE). Different forms of the disease are recognized although a consensus nomenclature is still missing 1 . Most of the patients present with a focal RPE leak that causes a spontaneously resolving, and sometimes recurrent serous detachment.…”

Section: Introductionmentioning

confidence: 99%

Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy

Matet

Jaworski

Bousquet

et al. 2020

Sci Rep

View full text Add to dashboard Cite

No systemic biomarker of Central Serous Chorioretinopathy (CSCR) has been identified. Lipocalin 2 (LCN2 or NGAL), alone or complexed with MMP-9 (NGAL/MMP-9), is increased in several retinal disorders. Serum levels of LCN2 and NGAL/MMP-9 were measured in CSCR patients (n = 147) with chronic (n = 76) or acute/recurrent disease (n = 71) and in age- and sex-matched healthy controls (n = 130). Samples with CRP > 5 mg/L, creatinine > 100 µmol/L, and/or urea > 7.5 mmol/L were excluded. Serum LCN2 was lower in CSCR patients than controls (81.4 ± 48.7 vs 107.3 ± 44.5 ng/ml, p < 0.0001), and lower in acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.006). Serum NGAL/MMP-9 was lower in CSCR patients than controls (47.2 ± 40.7 vs 74.1 ± 42.6, p < 0.0001), and lower in acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.002). A ROC curve showed that for LCN2 serum levels, the 80-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 80.3% sensitivity and 75.8% specificity, and for NGAL/MMP-9 serum levels, a 38-ng/ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 69.6% sensitivity and 80.3% specificity. In both acute and chronic CSCR, low serum LCN2 and NGAL/MMP-9, provide a biological link between the two CSCR forms, and potential susceptibility to oxidative stress and innate immune dysregulation in CSCR.

show abstract

“…Using ICGA, the extent of underlying choroidal abnormalities can be assessed. Based on the findings on multimodal imaging and the duration of symptoms, CSC is often categorized into acute CSC and chronic CSC (cCSC), although the classification is subject of debate [4]. While acute CSC usually resolves spontaneously within 4 months after the start of symptoms, cCSC can lead to irreversible visual impairment and a decreased quality of life [5,6].…”

Section: Introductionmentioning

confidence: 99%

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy

Rijssen

Dijk

Scholz

et al. 2020

Graefes Arch Clin Exp Ophthalmol

Self Cite

View full text Add to dashboard Cite

Purpose To evaluate the clinical outcomes after half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (cCSC) patients with pre-existent fovea-involving atrophy. Methods In this retrospective study, cCSC patients who had a window defect of the retinal pigment epithelium (RPE) on fluorescein angiography (FA), compatible with RPE atrophy, prior to half-dose PDT were included. Results Thirty-four cCSC eyes with typical findings of cCSC on multimodal imaging, and fovea-involving RPE atrophy on FA, were included. At the first visit after PDT (at a median of 1.8 months after half-dose PDT), 20 eyes (59%) had a complete resolution of SRF (p < 0.001), while this was the case in 19 eyes (56%) at final visit (median of 11.3 months after half-dose PDT; p < 0.001). The mean BCVA in Early Treatment of Diabetic Retinopathy Study letters was 71. 2 ± 15.9 at last visit before PDT, which increased to 74.1 ± 14.1 at first visit after PDT (p = 0.093, compared with baseline), and changed to 73.0 ± 19.1 at final visit (p = 0.392, compared with baseline). Both at first visit after PDT and at final visit, a significant decrease in subfoveal choroidal thickness was observed (p = 0.032 and p = 0.004, respectively). Conclusions Half-dose PDT in cCSC patients with pre-existing fovea-involving atrophy may lead to anatomical changes, but not to functional improvements. Ideally, cCSC should be treated with half-dose PDT before the occurrence of such atrophy.

show abstract

Discrepancy in current central serous chorioretinopathy classification

Cited by 45 publications

References 23 publications

Central Serous Chorioretinopathy Classification

Central Serous Chorioretinopathy Classification

Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy

Contact Info

Product

Resources

About